Citations

Showing 10 of 108119 citations.

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus
Schiff, David , Bent, Martin J. van den , Vogelbaum, Michael A. , Miller, C. Ryan , Taphoorn, Martin , Pope, Whitney B. , Brown, Paul D. , Platten, Michael , Jalali, Rakesh , Wen, Patrick Y. , van den Bent, Martin J , Platten, Michael , Wick, Wolfgang , Armstrong, Terri S. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | February 4, 2019 | Volume: 21 | Issue: 7 | Pages: 837-853

10.1093/neuonc/noz033 | PMID 30753579 Get It

Abstract The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and deletional analysis of cyclin-dependent kinase inhibitor 2A and 2B. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Recent, ongoing, and planned studies of radiation therapy and both cytotoxic and targeted chemotherapies are summarized, including both small molecule and immunotherapy approaches specifically targeting the mutant IDH protein.
Precision immunoprofiling to reveal diagnostic signatures for latent tuberculosis infection and reactivation risk stratification
Robison, Heather M., Escalante, Patricio , Valera, Enrique , Erskine, Courtney L. , Auvil, Loretta, Sasieta, Humberto C., Bushell, Colleen , Welge, Michael , Bailey, Ryan C

Mayo Clinic

Integrative Biology | February 4, 2019 | Volume: 11 | Issue: 1 | Pages: 16-25

10.1093/intbio/zyz001 | PMID 30722034 Get It

Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score
Woodard, Genevieve A. , Price, Elissa R.

Mayo Clinic

American Journal of Roentgenology | February 4, 2019 | Volume: 212 | Issue: 4 | Pages: 919-924

10.2214/ajr.18.20306 | PMID 30714832 Get It

Extracellular Vesicle‐Based Therapeutic Targeting of β‐Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer
Matsuda, Akiko , Ishiguro, Kaori, Patel, Tushar , Yan, Irene K. , Patel, Tushar

Mayo Clinic

Hepatology Communications | February 4, 2019 | Volume: 3 | Issue: 4 | Pages: 525-541

10.1002/hep4.1311 | PMID 30976743 Get It

Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death worldwide. Although HCC can respond to immune checkpoint inhibitors, such as monoclonal antibodies against programmed death 1 (PD‐1), many patients fail to respond or develop secondary resistance. Activation of Wnt/β‐catenin signaling can contribute to immune evasion. Mutations in β‐catenin are among the most frequent mutations associated with HCC. Thus, our aim was to directly target β‐catenin to enhance the therapeutic response to immune checkpoint inhibition. A synthetic transgenic mouse model of experimental HCC induced by tyrosine‐protein kinase Met/β‐catenin expression and extracellular vesicles (EVs) as a therapeutic delivery agent was used to evaluate the efficacy of directly targeting β‐catenin on the response to anti‐PD‐1. These studies showed that (1) oncogenic β‐catenin could be therapeutically targeted using a biological nanoparticle‐based delivery approach, (2) targeting β‐catenin using small interfering RNA (siRNA) delivered within EVs can reduce tumor growth, and (3) the therapeutic response to anti‐PD‐1 can be enhanced by concomitantly targeting β‐catenin using therapeutic EVs. These preclinical studies establish the efficacy of the use of biological nanoparticles as an endogenous delivery vehicle for therapeutic RNA delivery and support the use of therapeutic strategies targeting tumor‐intrinsic β‐catenin as an adjunct to anti‐PD‐1‐based therapy.Conclusion:Combination therapy with anti‐PD‐1 and β‐catenin siRNA delivered using biological nanoparticles provides an effective strategy for the treatment of HCC. This strategy could be further exploited into targeted approaches for immune potentiation by countering oncogene‐mediated resistance to immunotherapies.
Anterior cruciate ligament reconstruction with concomitant meniscal surgery: a systematic review and meta‐analysis of outcomes
Sarraj, Mohamed , Coughlin, Ryan P., Solow, Max, Simunovic, Nicole , Krych, Aaron J. , MacDonald, Peter B. , Ayeni, Olufemi R. , Ayeni, Olufemi R , Krych, Aaron J , Coughlin, Ryan P., Ekhtiari, Seper

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | February 4, 2019 | Volume: 27 | Issue: 11 | Pages: 3441-3452

10.1007/s00167-019-05389-3 | PMID 30719542 Get It

AbstractPurposeThe aim of this review was to compare the clinical outcomes of anterior cruciate ligament reconstruction (ACLR) with either meniscal repair or meniscectomy for concomitant meniscal injury. The primary hypothesis was that short‐term clinical outcomes (≤ 2‐year follow‐up) for ACLR concomitant with either meniscal repair or resection would be similar. The secondary hypothesis was that ACLR with meniscal repair would result in better longer term outcomes compared with meniscal resection.MethodsThe authors searched two online databases (EMBASE and MEDLINE) from inception until March 2018 for the literature on ACLR and concurrent meniscal surgery. Two reviewers systematically screened studies in duplicate, independently, and based on a priori criteria. Quality assessment was also performed in duplicate. The Knee injury and Osteoarthritis Outcome Score (KOOS) sub‐scale scores at 2 years post‐operatively were combined in a meta‐analysis of proportions using a random‐effects model.ResultsOf 2566 initial studies, 25 studies satisfied full‐text inclusion criteria. Mean follow‐up was 2.09 years, with a total sample of 37,087 subjects including controls. The meta‐analysis demonstrated equivocal results at 2 years, except for KOOS symptom scores which favoured meniscal resection over repair. Mean KT‐1000 side‐to‐side difference (SSD) scores were 1.51 ± 0.60 mm for meniscal repair, 1.96 ± 0.36 mm for meniscal resection, and 1.58 ± 0.20 for control patients (isolated ACLR). Medial meniscal repair showed decreased anterior knee joint laxity compared to medial meniscal resection (P < 0.001). Patients with meniscal repair had higher rates of re‐operation (13.3% vs 0.8% for meniscal resection, P < 0.001).ConclusionPatients with ACLR combined with meniscal resection demonstrate better symptoms at 2‐year follow‐up compared to patients with ACLR combined with meniscal repair. ACLR combined with meniscal repair results in decreased anterior knee joint laxity with evidence of improved patient‐reported outcomes in the long term, but also higher re‐operation rates.Level of evidenceIII.
A pragmatic approach to understand peripheral artery lumen surface stiffness due to plaque heterogeneity
Neumann, Erica E. , Young, Melissa , Erdemir, Ahmet

Mayo Clinic

Computer Methods in Biomechanics and Biomedical Engineering | February 4, 2019 | Volume: 22 | Issue: 4 | Pages: 396-408

10.1080/10255842.2018.1560427 | PMID 30712373 Get It

Intermittent bolus versus continuous infusion techniques for local anesthetic delivery in peripheral and truncal nerve analgesia: the current state of evidence
Jagannathan, Ram , Niesen, Adam D. , D’Souza, Ryan S. , Johnson, Rebecca L. , D'Souza, Ryan S , Jagannathan, Ram

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 4, 2019 | Volume: 44 | Issue: 4 | Pages: 447-451

10.1136/rapm-2018-100082 | PMID 30914472 Get It

Manually delivered intermittent bolus (MIB) and programmable intermittent bolus (PIB), alternatives to continuous infusion (CI), involve administering a set volume of solution at a set interval of time. The benefits of intermittent bolus techniques in truncal and peripheral nerve blockade (TPNB) are unclear, and studies have largely demonstrated conflicting results. Using MEDLINE, Embase, Google Scholar, and the Cochrane Library, we conducted an evidenced-based review of published randomized controlled trials comparing intermittent bolus and CI methods in TPNB. In total, 13 randomized controlled trials were identified and evaluated. Outcomes data addressed in these studies included assessments of pain, opioid and local anesthetic consumption, patient satisfaction, adverse events, and physical therapy metrics. The overall quality of current evidence was found to be low given the small sample sizes, heterogeneity of data, and the variations in intermittent bolus techniques between studies. At this time, we found limited supportive data to endorse MIB or PIB over CI in TPNB. While unable to provide data-driven conclusions for local anesthetic delivery methods at this time, we propose that future studies and quantitative analysis between techniques should be on an anatomic, site-specific basis, with greater focus on evaluation of opioid use, adverse events, patient satisfaction, and rehabilitative metrics.
A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Smith, Thomas J. , Razzak, A. Rab, Ensminger, Jennifer, Saiki, Catherine, Longo-Schoberlein, Denise, Loprinzi, Charles L. , Smith, Thomas J , Blackford, Amanda

Mayo Clinic

Journal of Palliative Care | February 4, 2019 | Volume: 35 | Issue: 1 | Pages: 53-58

10.1177/0825859719827589 | PMID 30714486 Get It

Background: Chemotherapy-induced peripheral neuropathy (CIPN) affects 30% to 40% of patients with cancer with long-lasting disability. Scrambler therapy (ST) appeared to benefit patients in uncontrolled trials, so we performed a randomized sham-controlled Phase II trial of ST. Methods: The primary end point was “average pain” after 28 days on the Numeric Rating Scale. Each received ten 30-minute sessions of ST on the dermatomes above the painful areas, or sham treatment on the back, typically at L3-5 where the nerve roots would enter the spinal cord. Outcomes included the Brief Pain Inventory (BPI)-CIPN and the EORTC CIPN-20 scale. Patients were evaluated before treatment (day 0), day 10, and days 28, 60, and 90. Results: Data regarding pain as a primary outcome were collected for 33 of the 35 patients. There were no significant differences between the sham and the “real” ST group at day 10, 28, 60, or 90, for average pain, the BPI, or EORTC CIPN-20. Individual responses were noted during the ST treatment on the real arm, but most dissipated by day 30. There was improvement in the sensory subscale of the CIPN-20 at 2 months in the “real” group ( P = .14). All “real” patients wanted to continue treatment if available. Discussion: We observed no difference between sham and real ST CIPN treatment. Potential reasons include at least the following: ST does not work; the sham treatment had some effect; small sample size with heterogeneous patients; misplaced electrodes on an area of nonpainful but damaged nerves; or a combination of these factors.
Microwave Preparation of and One-strip Paper Chromatography for Technetium Tc 99m Teboroxime
Wilson, Mark E., Hung, Joseph C., Wilson, Mark E.

Mayo Clinic

American Journal of Health-System Pharmacy | February 3, 2019 | Volume: 50 | Issue: 11 | Pages: 2376-2379

10.1093/ajhp/50.11.2376 Get It

The evolution and impact of sarcopenia pre‐ and post‐liver transplantation
Bhanji, Rahima A. , Takahashi, Naoki , Moynagh, Michael R., Narayanan, Praveena , Angirekula, Mounika, Mara, Kristin C. , Dierkhising, Ross , Watt, Kymberly D. , Dierkhising, Ross A, Mara, Kristin C , Takahashi, Naoki

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 3, 2019 | Volume: 49 | Issue: 6 | Pages: 807-813

10.1111/apt.15161 | PMID 30714184 Get It

Summary Background Sarcopenia is associated with both increased wait‐list mortality and mortality following liver transplantation. Aims To determine the course of sarcopenia from transplant evaluation until 1 year post‐transplant, and its implications on hospitalisation and mortality following liver transplantation. Methods Two hundred and ninety‐three transplant recipients from 2002 to 2006 had pre‐transplant CT scans analysed at the third lumbar region for sarcopenia, myosteatosis and abdominal visceral fat content. Half the recipients had post‐transplant CT scan for interpretation (161/293). Results Sarcopenia was present in 146/293 (50%) of the patients pre‐transplant. There was a significant decrease in muscle mass (loss 2.0 ± 4.9 cm 2 /m 2 ; P < 0.001), and an increase in myosteatosis while awaiting liver transplantation. There was no significant change in abdominal visceral fat. For every 1 cm 2 /m 2 decrease in muscle mass there was an increase in post‐transplant length of stay by 0.36 days ( P = 0.005). Post‐transplant, 98/161 (61%) of patients with CT imaging had sarcopenia (25 de novo and 73 persistent), with continued increase in myosteatosis, lower Hounsfield units (−5.0 [IQR −8.6 to 0.1]; P < 0.001) and an increase in abdominal visceral fat (4.9 [IQR −4.4 to 15.6] cm 2 /m 2 ; P < 0.001). There was no statistically significant difference in 1‐year mortality in patients with de novo sarcopenia compared to patients with sarcopenia both pre‐ and post‐transplant (HR 1.88; P = 0.088). Conclusions Sarcopenia progresses up to 1 year following liver transplantation and is associated with an increase in post‐transplant length of stay.